TNFRSF1B and clear cell renal carcinoma: Quantification of percentage of TUNEL+CD133+cells from normal kidney (NK‐CD133+cells) and clear cell renal carcinoma (ccRCC‐CD133+CSCs) alone or in combination with immunostaining for pMLKLSer358 or Clv‐Casp3p175 following treatment with wtTNF, R1TNF, or R2TNF (30 min/37°C) or with siRNA targeting TNFR2, STAT3, or negative controls (UT and NTsiRNA) at 72h (37°C)